Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (121)
  2. Journal Article (92)
  3. Review (7)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
  7. Research Letter (1)
Groups
  1. Breast Medicine Service (225)
  2. Department of Medicine (225)
  3. Solid Tumor Oncology Division (225)
  4. GSK Faculty (59)
  5. Survivorship Research (48)
  6. Hematology-Oncology Fellows (46)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (29)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (31)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (11)
  5. New England Journal of Medicine (6)
  6. European Journal of Cancer (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (49)
  3. Oxford University Press (23)
  4. Elsevier Inc. (17)
  5. Springer (7)
  6. Massachusetts Medical Society (6)

More Publishers

Results (225)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Head-to-head evaluation of (18)F-FES and (18)F-FDG PET/CT in metastatic invasive lobular breast cancer
    Journal Article

    Ulaner, G. A.; Jhaveri, K.; Chandarlapaty, S.; Hatzoglou, V.; Riedl, C. C.; Lewis, J. S.; Mauguen, A.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Phase I basket study of taselisib, an isoform-selective PI3K inhibitor, in patients with PIK3CA-mutant cancers
    Journal Article

    Jhaveri, K.; Chang, M. T.; Juric, D.; Saura, C.; Gambardella, V.; Melnyk, A.; Patel, M. R.; Ribrag, V.; Ma, C. X.; Aljumaily, R.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • Compound PIK3CA mutations support a mutational dose-response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer
    Meeting Abstract

    Vasan, N.; Johnson, J.; Shao, H.; Razavi, P.; Gorelick, A.; Ladewig, E.; Antoine, A.; Shah, H.; Toska, E.; Xu, G.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer
    Meeting Abstract

    Lim, E.; Jhaveri, K. L.; Perez-Fidalgo, J. A.; Bellet, M.; Boni, V.; Garcia, J. M. P.; Estevez, L.; Bardia, A.; Turner, N. C.; Villanueva, R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients
    Meeting Abstract

    Barrios, D. M.; Wang, D. G.; Blinder, V. S.; Bromberg, J.; Drullinsky, P.; Funt, S. A.; Jhaveri, K. L.; Lake, D.; Lyons, T.; Modi, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC)
    Meeting Abstract

    Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2- BC)
    Meeting Abstract

    Gambardella, V.; Cervantes, A.; Bedard, P. L.; Hamilton, E. P.; Italiano, A.; Jhaveri, K.; Juric, D.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save